26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt or derivative thereof, together with a pharmaceutically acceptable carrier.

27. A compound according to any one of claims 1 to 25, for use in a method of medical treatment.

28. Use of a~~A~~ compound according to any one of claims 1 to 25~~, for use~~ in the manufacture of a medicament for preventing weight gain or promoting weight loss in a subject in need thereof.

29. Use of a~~A~~ compound according to any one of claims 1 to 25~~, for use~~ in the manufacture of a medicament for ~~a method of~~ improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio.

30. Use of a~~A~~ compound according to any one of claims 1 to 25~~, for use~~ in the manufacture of a medicament for treating ~~a method of treatment of~~ a condition caused or characterised by excess body weight, e.g. the treatment and/or prevention of obesity, morbid obesity, obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced sleep apnea, metabolic syndrome, pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension, atherogenic dyslipidaemia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or microvascular disease.

~~31. Use of a compound according to any one of claims 1 to 25 for preventing weight gain or promoting weight loss in a subject in need thereof.~~

~~32. Use of a compound according to any one of claims 1 to 25 in a method of improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDL/LDL ratio in a subject in need thereof.~~

~~33. Use of a compound according to any one of claims 1 to 25 in a method of treatment of a condition caused or characterised by excess body weight, e.g. the treatment and/or prevention of obesity, morbid obesity, obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced sleep apnea, pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension, atherogenic dyslipidaemia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or microvascular disease in a subject in need thereof.~~

3431. A compound~~,~~ or use ~~or method~~ according to any one of claims 27 to 3330, wherein said compound is to be administered as part of a combination therapy together with an agent for treatment of diabetes, obesity, dyslipidaemia, or hypertension.

3532. A compound~~,~~ or use ~~or method~~ according to claim 3431, wherein said agent for treatment of diabetes is metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or an insulin analogue.

~~36~~33. A compound~~,~~ or use ~~or method~~ according to claim ~~34~~31, wherein said agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY or an analogue thereof, a cannabinoid receptor 1 antagonist, a lipase inhibitor, a melanocortin receptor 4 agonist, or a melanin concentrating hormone receptor 1 antagonist.

~~37~~34. A compound~~,~~ or use ~~or method~~ according to claim ~~34~~31, wherein said agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, a diuretic, a beta-blocker, or a calcium channel blocker.

~~38~~35. A compound~~,~~ or use ~~or method~~ according to claim ~~34~~31, wherein said agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin or a cholesterol absorption inhibitor.